<DOC>
	<DOCNO>NCT00950768</DOCNO>
	<brief_summary>In study randomise induction treatment either receive two course melphalan 200 mg/m2 ( MEL200 ) two course melphalan 100 mg/m2 ( MEL100 ) . Informed consent obtain upon enrolment . Inclusion criterion include : diagnosis untreated Durie e Salmon stage IIA-IIIB measurable multiple myeloma ; age &lt; 65 year . Exclusion criterion include : prior treatment myeloma ; abnormal cardiac function , define systolic ejection fraction &lt; 50 % ; abnormal pulmonary spirometry test ; serum bilirubins &gt; 2.5 time normal ALAT and/or ASAT &gt; 2 time normal ; seropositivity HIV , HCV HBV , active non-hematologic malignancy . Induction therapy , PBSC mobilization , autografting Initial treatment plan include induction chemotherapy 2 course vincristine , 1 mg/m2 day 1 , adriamycin , 50 mg/m2 day 1 , dexamethasone , 40mg/day day 1-4 , administer 28 day apart , follow peripheral blood stem cell ( PBSC ) mobilisation harvest 1 2 cycle cyclophosphamide , 4 g/m2 , G-CSF , 10 ug/kg give i.v . subcutaneously . After least one month PBSC collection , autografting consist melphalan , 200 mg/m2 melphalan , 100 mg/m2 , day -2 , cryopreserved PBSC infusion day 0 . Patients receive G-CSF , 5 ug/kg , day +3 neutrophil count &gt; 1000/ul achieve . Supportive care toxicity grade Following autografting , patient receive standard prophylaxis bacterial fungal infection ; herpes simplex varicella-zoster virus reactivation ; Pneumocystis carinii . Cytomegalovirus CMV reactivation monitor level CMV antigenemia and/or serum CMV DNA level treat ganciclovir foscarnet clinically indicate . Standard criterion ( Common Toxicity Criteria version 3.0 ) use grade hematological non-hematological toxicity .</brief_summary>
	<brief_title>Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 Newly Diagnosed Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Inclusion criterion include : diagnosis untreated Durie &amp; Salmon stage IIAIIIB measurable multiple myeloma ; age &lt; 65 year . Exclusion criterion include : prior treatment myeloma ; abnormal cardiac function , define systolic ejection fraction &lt; 50 % ; abnormal pulmonary spirometry test ; serum bilirubins &gt; 2.5 time normal ALAT and/or ASAT &gt; 2 time normal ; seropositivity HIV , HCV HBV , active nonhematologic malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Autologous transplantation</keyword>
</DOC>